BRPI1012201A2 - composto anticacerígeno e composição farmacêutica que o contém - Google Patents

composto anticacerígeno e composição farmacêutica que o contém

Info

Publication number
BRPI1012201A2
BRPI1012201A2 BRPI1012201A BRPI1012201A BRPI1012201A2 BR PI1012201 A2 BRPI1012201 A2 BR PI1012201A2 BR PI1012201 A BRPI1012201 A BR PI1012201A BR PI1012201 A BRPI1012201 A BR PI1012201A BR PI1012201 A2 BRPI1012201 A2 BR PI1012201A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
anticancer compound
anticancer
compound
Prior art date
Application number
BRPI1012201A
Other languages
English (en)
Inventor
Alain Krick
Cécile Combeau
François Clerc
Jean-Christopher Carry
Laurent Schio
Michel Cheve
Sylvette Lachaud
Sylvie Gontier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI1012201A2 publication Critical patent/BRPI1012201A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
BRPI1012201A 2009-05-18 2010-05-17 composto anticacerígeno e composição farmacêutica que o contém BRPI1012201A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant
PCT/FR2010/050948 WO2010133794A1 (fr) 2009-05-18 2010-05-17 Compose anticancéreux et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
BRPI1012201A2 true BRPI1012201A2 (pt) 2016-04-05

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012201A BRPI1012201A2 (pt) 2009-05-18 2010-05-17 composto anticacerígeno e composição farmacêutica que o contém

Country Status (34)

Country Link
US (2) US9073917B2 (pt)
EP (1) EP2432766B1 (pt)
JP (1) JP5656981B2 (pt)
KR (1) KR20120032483A (pt)
CN (1) CN102459193B (pt)
AR (1) AR076686A1 (pt)
AU (1) AU2010251013B2 (pt)
BR (1) BRPI1012201A2 (pt)
CA (1) CA2762233C (pt)
CL (1) CL2011002930A1 (pt)
CO (1) CO6400138A2 (pt)
CY (1) CY1114850T1 (pt)
DK (1) DK2432766T3 (pt)
EA (1) EA021084B1 (pt)
ES (1) ES2430989T3 (pt)
FR (1) FR2945535B1 (pt)
HR (1) HRP20130959T1 (pt)
IL (1) IL216361A0 (pt)
JO (1) JO2852B1 (pt)
MA (1) MA33356B1 (pt)
ME (1) ME01542B (pt)
MX (1) MX2011012356A (pt)
MY (1) MY152995A (pt)
NZ (1) NZ596464A (pt)
PL (1) PL2432766T3 (pt)
PT (1) PT2432766E (pt)
RS (1) RS53002B (pt)
SG (1) SG176169A1 (pt)
SI (1) SI2432766T1 (pt)
SM (1) SMT201400005B (pt)
TW (1) TWI441822B (pt)
UY (1) UY32644A (pt)
WO (1) WO2010133794A1 (pt)
ZA (1) ZA201108447B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
US9365520B2 (en) 2014-07-01 2016-06-14 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20190136063A (ko) 2017-04-05 2019-12-09 더 브로드 인스티튜트, 인코퍼레이티드 글리코겐 신타제 키나제 3 (gsk3) 억제제로서의 트리시클릭 화합물 및 그의 용도
CN117337292A (zh) 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025233174A1 (en) * 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2391291A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
KR20030076650A (ko) 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
PT1746097E (pt) 2005-07-20 2010-04-15 Aventis Pharma Sa Heterociclos fundidos de 1,4-di-hidropiridina, processo para a sua preparação, utilização e composições que os contêm
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
AU2010251013A1 (en) 2011-12-08
JP2012527436A (ja) 2012-11-08
WO2010133794A1 (fr) 2010-11-25
MX2011012356A (es) 2011-12-14
TW201100418A (en) 2011-01-01
UY32644A (es) 2010-12-31
IL216361A0 (en) 2012-01-31
US9221817B2 (en) 2015-12-29
ES2430989T3 (es) 2013-11-22
PL2432766T3 (pl) 2013-12-31
TWI441822B (zh) 2014-06-21
ME01542B (me) 2014-04-20
JO2852B1 (en) 2015-03-15
EP2432766A1 (fr) 2012-03-28
AU2010251013B2 (en) 2015-08-20
CL2011002930A1 (es) 2012-06-29
CA2762233A1 (fr) 2010-11-25
HRP20130959T1 (hr) 2013-11-22
CN102459193B (zh) 2014-08-27
DK2432766T3 (da) 2013-10-28
NZ596464A (en) 2014-01-31
SG176169A1 (en) 2011-12-29
SI2432766T1 (sl) 2013-11-29
CY1114850T1 (el) 2016-12-14
US20150266877A1 (en) 2015-09-24
SMT201400005B (it) 2014-03-07
FR2945535B1 (fr) 2011-06-10
EP2432766B1 (fr) 2013-07-17
HK1167388A1 (en) 2012-11-30
FR2945535A1 (fr) 2010-11-19
JP5656981B2 (ja) 2015-01-21
ZA201108447B (en) 2013-01-30
US20120220621A1 (en) 2012-08-30
EA021084B1 (ru) 2015-04-30
EA201171429A1 (ru) 2012-05-30
CA2762233C (fr) 2017-11-28
CN102459193A (zh) 2012-05-16
RS53002B (sr) 2014-04-30
US9073917B2 (en) 2015-07-07
AR076686A1 (es) 2011-06-29
MA33356B1 (fr) 2012-06-01
KR20120032483A (ko) 2012-04-05
MY152995A (en) 2014-12-31
PT2432766E (pt) 2013-10-23
CO6400138A2 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
SMT201400005B (it) Composto anticancro e composizione farmaceutica che l contiene
DK3097925T3 (da) Farmaceutisk sammensætning
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI1004940A2 (pt) composição farmacêutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
PT2796129E (pt) Composição contendo palmitoiletanolamida ultramicronizada
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
ES2465478T8 (es) Composiciones farmacéuticas que comprenden brivaracetam
BRPI1015939A2 (pt) composição farmacêutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2285413T3 (da) Farmaceutisk sammensætning
IT1394400B1 (it) Composizioni farmaceutiche
EP2236149A4 (en) MEDICAL COMPOSITION
DK2542224T3 (da) Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
BRPI0921313A2 (pt) composição farmaucêutica
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica
BRPI0921301A2 (pt) composição farmacêutica
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.